Alzheimer’s disease (AD) is a complex and multifaced neurodegenerative disorder for which the precise pathological molecular mechanisms are still not completely known. In last years, rational multi-target drug design methods, which combine multiple molecules having complementary modes of action, have been increasingly used in the development of anti-AD drugs. In the present perspective, a new multitarget therapeutic approach, based on an inspired proteolysis targeting chimera (PROTAC) construction, is examined as a future applicable strategy to modulate the favourable cross-interactions between transthyretin and Aβ 1–42 peptide
Application of PROTAC strategy to TTR-Aβ protein-protein interaction for the development of Alzheimer’s disease drugs
Susanna Nencetti;Elisabetta Orlandini;Lidia Ciccone
2021-01-01
Abstract
Alzheimer’s disease (AD) is a complex and multifaced neurodegenerative disorder for which the precise pathological molecular mechanisms are still not completely known. In last years, rational multi-target drug design methods, which combine multiple molecules having complementary modes of action, have been increasingly used in the development of anti-AD drugs. In the present perspective, a new multitarget therapeutic approach, based on an inspired proteolysis targeting chimera (PROTAC) construction, is examined as a future applicable strategy to modulate the favourable cross-interactions between transthyretin and Aβ 1–42 peptideFile | Dimensione | Formato | |
---|---|---|---|
NeuralRegenRes-2021.pdf
accesso aperto
Descrizione: Articolo Principale
Tipologia:
Versione finale editoriale
Licenza:
Creative commons
Dimensione
865.62 kB
Formato
Adobe PDF
|
865.62 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.